- Home
- UFCS vs PRTA Comparison
UFCS vs PRTA Comparison
Compare UFCS & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- PRTA
- Stock Information
- Founded
- UFCS 1946
- PRTA 2012
- Country
- UFCS United States
- PRTA Ireland
- Employees
- UFCS N/A
- PRTA N/A
- Industry
- UFCS Property-Casualty Insurers
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- UFCS Finance
- PRTA Health Care
- Exchange
- UFCS Nasdaq
- PRTA Nasdaq
- Market Cap
- UFCS 642.7M
- PRTA 643.0M
- IPO Year
- UFCS N/A
- PRTA N/A
- Fundamental
- Price
- UFCS $26.48
- PRTA $14.11
- Analyst Decision
- UFCS Hold
- PRTA Buy
- Analyst Count
- UFCS 1
- PRTA 7
- Target Price
- UFCS $26.00
- PRTA $46.50
- AVG Volume (30 Days)
- UFCS 151.3K
- PRTA 672.2K
- Earning Date
- UFCS 02-11-2025
- PRTA 02-13-2025
- Dividend Yield
- UFCS 2.42%
- PRTA N/A
- EPS Growth
- UFCS N/A
- PRTA N/A
- EPS
- UFCS 1.94
- PRTA N/A
- Revenue
- UFCS $1,207,451,000.00
- PRTA $133,350,000.00
- Revenue This Year
- UFCS N/A
- PRTA $56.89
- Revenue Next Year
- UFCS $11.31
- PRTA N/A
- P/E Ratio
- UFCS $13.59
- PRTA N/A
- Revenue Growth
- UFCS 10.95
- PRTA N/A
- 52 Week Low
- UFCS $18.04
- PRTA $11.70
- 52 Week High
- UFCS $31.70
- PRTA $34.65
- Technical
- Relative Strength Index (RSI)
- UFCS 39.63
- PRTA 50.40
- Support Level
- UFCS $25.20
- PRTA $13.00
- Resistance Level
- UFCS $27.43
- PRTA $14.40
- Average True Range (ATR)
- UFCS 0.72
- PRTA 0.99
- MACD
- UFCS -0.18
- PRTA 0.04
- Stochastic Oscillator
- UFCS 33.60
- PRTA 59.11
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).